Diagnostic Biomarkers for the Early Detection of Woman's Cancer, Including Ovarian, Uterine and Colon

Development of more effective therapeutics against human ovarian cancerTreatment for advanced-stage ovarian cancer with recurrent disease or failed first-line chemotherapySuperior safety profile with little to no side effects

Ovarian cancer therapeuticsGynecologic cancers therapeutics

A team of scientists led by Dr. Farias-Eisner and Dr. Reddy discovered a human protein, apoA-I as a new anticancer agent. ApoA-I is the major component of the good cholesterol HDL, and it plays an important role in regulating lipid transport, inflammation, and oxidative stress. The researchers first observed reduced apoA-I levels in ovarian cancer patients, suggesting that the protein might be protective and could prevent cancer from spreading. A series of experiments provide solid evidence for their hypothesis. Transgenic mice expressing the human apoA-I showed improved survival and reduced tumor development compared to regular mice when induced with ovarian cancer. ApoA-I mimetic peptides inhibited the viability of chemotherapy-resistant human ovarian cancer cell lines. The study was published in the November 1, 2010, early online edition of the Proceedings of the National Academy of Sciences. ApoA-I is a natural human protein; it has the potential for a favorable safety profile when compared to traditional chemotherapies. The discovery offers promising therapeutics to fight against human ovarian cancers at various stages, even recurrent cancers that are resistant to traditional chemotherapy.

Patent Number: US20110027894A1
Application Number: US2010860293A
Inventor: Farias-Eisner, Robin | Reddy, Srinivasa T.
Priority Date: 14 Jul 2004
Priority Number: US20110027894A1
Application Date: 20 Aug 2010
Publication Date: 3 Feb 2011
IPC Current: G01N0033574
US Class: 436064
Assignee Applicant: The Regents of the University of California
Title: BIOMARKERS FOR DETECTION OF EARLY- AND LATE-STAGE ENDOMETRIAL CANCER
Usefulness: BIOMARKERS FOR DETECTION OF EARLY- AND LATE-STAGE ENDOMETRIAL CANCER
Summary: The method is useful for screening for ovarian neoplasia in a subject (claimed).
Novelty: Screening for ovarian neoplasia in a subject comprises measuring hemoglobin in a tissue sample of the subject, and comparing the measured hemoglobin of the tissue sample to a measurement of hemoglobin in normal tissue

Disease Diagnostic/Treatment

Cancer/Tumor

7670792

State Of Development

ApoA-I and apoA-I mimetic peptides have been shown to strongly block tumor growth and significantly improve survival in a mouse model of human ovarian cancer. In vitro experiments have shown that apoA-I mimetic peptides inhibit the viability of human ovarian cancer cell lines resistant to cis-platinum chemotherapy.

Background

Ovarian cancer is the 4th leading cause of cancer death in women. Each year in the United States, about 23,000 women are diagnosed with ovarian cancer, and more than 13,000 women die from this disease. Current therapies typically involve surgery to remove tumors followed by chemotherapy to eradicate any remaining cancer cells. Early detection is important, however, more than 85% of ovarian cancers are found at late stages when tumor growth has spread beyond the ovaries. Women with advanced ovarian cancer generally have a high recurrence rate (about 70%) and poor long-term survival. A safer and more effective therapy for late-stage and recurrent ovarian cancers is much needed.

Related Materials

Apolipoprotein A-I (apoA-I) and apoA-I mimetic peptides inhibit tumor development in a mouse model of ovarian cancer.
Drug found to inhibit ovarian cancer growth. (Press Release)

Additional Technologies by these Inventors

• Use of ApoA-1 to Treat and Prevent Pro-Inflammatory Conditions

Tech ID/UC Case

21722/2004-159-0

Related Cases

2004-159-0

USA

Desktop View